Phosphinic acid inhibitors of matrix metalloproteinases

被引：48
|
作者：
Caldwell, CG
Sahoo, SP
Polo, SA
Eversole, RR
Lanza, TJ
Mills, SG
Niedzwiecki, LM
IzquierdoMartin, M
Chang, BC
Harrison, RK
Kuo, DW
Lin, TY
Stein, RL
Durette, PL
Hagmann, WK
机构：
[1] MERCK SHARP & DOHME RES LABS,DEPT MED CHEM,RAHWAY,NJ 07065
[2] MERCK SHARP & DOHME RES LABS,DEPT ENZYMOL,RAHWAY,NJ 07065
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1996年 / 6卷 / 03期
关键词：
D O I：
10.1016/0960-894X(96)00023-6
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The matrix metalloproteinase stromelysin-1 (MMP-3) is inhibited more strongly by peptidyl phosphinic acid 7 than by its corresponding phosphonamidate and phosphonate analogs. Extending a benzyl group at P-1' to a phenylethyl group in 8 further increases the potency (K-i = 1.4 nM). Enhanced potency with an extended substituent into the P-3 region was observed.
引用
收藏
页码：323 / 328
页数：6
相关论文
共 50 条
  • [41] Matrix metalloproteinases and their inhibitors in aqueous humor
    Huang, SH
    Adamis, AP
    Wiederschain, DG
    Shima, DT
    Shing, Y
    Moses, MA
    EXPERIMENTAL EYE RESEARCH, 1996, 62 (05) : 481 - 489
  • [42] Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases
    Dive, V
    Andarawewa, KL
    Boulay, A
    Matziari, M
    Beau, F
    Guerin, E
    Rousseau, B
    Yiotakis, A
    Rio, MC
    INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (05) : 775 - 781
  • [43] Role of matrix metalloproteinases and their inhibitors in retinoblastoma
    Mohan, A
    Nalini, V
    Shanmugam, MP
    Biswas, J
    Krishnakumar, S
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [44] Circulating matrix metalloproteinases and their inhibitors in hypertension
    Fontana, Vanessa
    Silva, Pamela S.
    Gerlach, Raquel F.
    Tanus-Santos, Jose E.
    CLINICA CHIMICA ACTA, 2012, 413 (7-8) : 656 - 662
  • [45] The Pharmacological TAILS of Matrix Metalloproteinases and Their Inhibitors
    Das, Nabangshu
    Benko, Colette
    Gill, Sean E.
    Dufour, Antoine
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 17
  • [46] Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
    Tanaka, Komei
    Essick, Eric E.
    Connors, Lawreen H.
    Seldin, David C.
    Sam, Flora
    CIRCULATION, 2011, 124 (21)
  • [47] Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas
    Söderström, M
    Aro, HT
    Ahonen, M
    Johansson, N
    Aho, A
    Ekfors, T
    Böhling, T
    Kähäri, VM
    Vuorio, E
    APMIS, 2001, 109 (04) : 305 - 315
  • [48] Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes
    Bhalla, Vikas
    Georgiopoulou, Vasiliki V.
    Azeem, Ali A.
    Marti, Catherine N.
    Cole, Robert T.
    Laskar, Sonjoy R.
    De Staercke, Christine
    Hooper, W. Craig
    Smith, Andrew L.
    Kalogeropoulos, Andreas P.
    Butler, Javed
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 151 (02) : 237 - 239
  • [49] Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
    Tanaka, Komei
    Essick, Eric E.
    Doros, Gheorghe
    Tanriverdi, Kahraman
    Connors, Lawreen H.
    Seldin, David C.
    Sam, Flora
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2013, 2 (02): : e005868
  • [50] Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis
    Hoheisel, G
    Sack, U
    Hui, DSC
    Huse, K
    Chan, KS
    Chan, KK
    Hartwig, K
    Schuster, E
    Scholz, GH
    Schauer, J
    TUBERCULOSIS, 2001, 81 (03) : 203 - 209
12345